Evidence map›Paper›PMID 35043385›Full record

ArticleInternational urology and nephrology2022

Prognostic value of metabolic syndrome in renal structural changes in type 2 diabetes.

Lijun Zhao, Yutong Zou, Lin Bai, Li Zhou, Honghong Ren, Yucheng Wu, Yiting Wang, Shuangqing Li, Qiaoli Su, Linqiao Tang and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. The Triglyceride Glucose (TyG) Index as a Sensible Marker for Identifying Insulin Resistance and Predicting Diabetic Kidney Disease.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Lijun ZhaoDepartment of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.
Yutong ZouDepartment of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.
Lin BaiHistology and Imaging Platform, Core Facility of West China Hospital, Chengdu, Sichuan, China.
Li ZhouHistology and Imaging Platform, Core Facility of West China Hospital, Chengdu, Sichuan, China.
Honghong RenDepartment of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.
Yucheng WuDepartment of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.
Yiting WangDepartment of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.
Shuangqing LiDivision of General Practice, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Qiaoli SuDivision of General Practice, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Linqiao TangHistology and Imaging Platform, Core Facility of West China Hospital, Chengdu, Sichuan, China.
Yuancheng ZhaoDepartment of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.
Huan XuDivision of Pathology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Lin LiDivision of Pathology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Zhonglin ChaiDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
Mark E CooperDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
Nanwei TongDivision of Endocrinology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, China. tongnw@scu.edu.cn.
Jie ZhangHistology and Imaging Platform, Core Facility of West China Hospital, Chengdu, Sichuan, China.
Fang LiuDepartment of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China. liufangfh@163.com.ORCID http://orcid.org/0000-0003-1121-3004
Sichuan University · CNMonash University · AU

Funding

Key Research and Development Project of Sichuan Science and Technology Department 19ZDYF1273National Natural Science Foundation of China 81670662National Natural Science Foundation of China 81970626Postdoctoral Research Foundation of Sichuan University 2021SCU12029
6 · The paper itself

Abstract

purposeTo investigate the prognostic value of metabolic syndrome (MetS) and its relationship with renal structure changes in patients with type 2 diabetes and associated diabetic nephropathy (DN).

methods411 Chinese patients with type 2 diabetes and biopsy-confirmed DN were enrolled in this retrospective study. MetS was defined according to the modified criteria of the 2005 International Diabetes Federation. Baseline demographics and clinical information at the time of renal biopsy were extracted from the hospital's electronic medical records system. Renal pathological findings were assessed according to Renal Pathology Society system. Univariate and multivariate logistic regression analyses were performed to define the pathological covariates associated with MetS. A competing risk model, with death as the competing risk, was used to estimate the sub-distribution hazard ratio (SHR) of MetS for end-stage kidney disease (ESKD).

results224 (55%) patients had MetS. Patients with MetS had poor renal function and more severe interstitial fibrosis tubular atrophy scores (IFTA) than those without MetS. Multivariate logistic regression analysis revealed that IFTA was significantly associated with MetS (odds ratio per score increase 1.45, 95% confidence interval [CI] 1.02-2.05). Of the patients with DN at risk, 40% of patients progressed to ESKD. After adjusting for renal function and pathological parameters, the presence of MetS was an independent predictor for progression to ESKD (SHR 1.93, 95% CI 1.34-2.79). The SHRs for progression to ESKD also increased as the number of MetS components increased. Additionally, adding the IFTA scores improved the prognostic power of a model that only contained MetS and clinical covariates for predicting future ESKD.

conclusionMetS is an independent prognostic predictor of ESKD in patients with T2D and DN, while adding the IFTA scores increased the prognostic value of MetS for renal outcome.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesKidney Failure, ChronicMetabolic SyndromeDisease ProgressionHumansKidneyPrognosisRetrospective StudiesDiabetic nephropathyEnd-stage kidney diseaseInterstitial fibrosisMetabolic syndromeTubular atrophyType 2 diabetes

Identifiers

PMID35043385
OpenAlexW4205726488

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.